EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas

Emanuela Esposito iD, Giusy Marra iD, Rosa Catalano iD, Sara Maioli iD, Emma Nozza iD, Anna Maria Barbieri iD, Constanze Hantel iD, Guido Di Dalmazi iD, Sandra Sigala iD, Jens Geginat iD, Elisa Cassinotti iD, Ludovica Baldari iD and 6 more

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35239 ↗

At a glance

Journal article in International Journal of Cancer, 2025. Written by Emanuela Esposito and 17 co-authors. Institution: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Major MEDLINE topics: Protein-Tyrosine Kinases, Cell Cycle Proteins, Adrenocortical Carcinoma, Filamins. Cited 8 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: Associazione Italiana per la Ricerca sul Cancro (AIRC) grant to E.P., Progetti di Ricerca di Interesse Nazionale (PRIN) grants to E.P., Ricerca Corrente Funds from the Italian Ministry of Health to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Filamin A (FLNA) is poorly expressed in adrenocortical carcinomas (ACC) compared to adenomas (ACA). Its presence is associated to a less aggressive tumour behaviour, potentially due to its role in negatively regulating IGF1R signalling. Upregulation of G2/M Wee1 kinase was shown in FLNA‐deficient mouse neural progenitor cells, and it has been reported in several tumours. This study explored Wee1 expression in ACC and its regulation by FLNA, the effects of Wee1 inhibitor AZD1775, and the impact of FLNA on its efficacy in ACC cell lines and primary cells. Analysis of FLNA and Wee1 proteins revealed elevated Wee1 and reduced FLNA in ACC compared to normal adrenal gland. FLNA knockdown increased Wee1 protein in NCI‐H295R, MUC‐1, and in primary ACC cells. Higher p‐CDK1 and cyclin B1 were shown in FLNA‐silenced MUC‐1, while decreased Wee1, p‐CDK1 and cyclin B1 resulted after FLNA overexpression. Wee1 reduction was reverted by lactacystin treatment and FLNA transfection increased p‐Wee1 (Ser123), suggesting FLNA's role in targeting Wee1 for degradation. AZD1775 dose‐dependently reduced proliferation and viability in ACC cell lines and primary cultures, and it triggered MUC‐1 cell death. Similar effects were induced by Wee1 silencing. FLNA depletion augmented AZD1775's efficacy in reducing proliferation and potentiating apoptosis in MUC‐1 and primary cells. In conclusion, we demonstrated that FLNA regulates Wee1 expression by promoting its degradation, suggesting that low FLNA typical of ACC leads to increased Wee1 with consequent cancer cells growth. It proposes Wee1 inhibition as a new potential therapeutic approach for ACC, particularly for those lacking FLNA.

Subjects

MeSH terms (MEDLINE)

Protein-Tyrosine KinasesCell Cycle ProteinsAdrenocortical CarcinomaFilaminsAdrenal Cortex NeoplasmsPyrimidinonesPyrazolesNuclear ProteinsHumansCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticCyclin B1FemaleProtein Kinase InhibitorsCDC2 Protein KinasePyrimidines

Author keywords

Wee1adavosertibadrenocortical carcinomascell cycle regulationfilamin Atherapeutic target

Substances

WEE1 protein, humanProtein-Tyrosine KinasesCell Cycle ProteinsFilaminsPyrimidinonesFLNA protein, humanPyrazolesNuclear ProteinsadavosertibCyclin B1

Authors and institutions

  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • PhD Programme in Experimental Medicine, University of Milan, Milan, Italy.
  • PhD Programme in Translational Medicine, University of Milan, Milan, Italy.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland.
  • Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
  • Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID profiles: Emanuela Esposito, Giusy Marra, Rosa Catalano, Sara Maioli, Emma Nozza, Anna Maria Barbieri, Constanze Hantel, Guido Di Dalmazi, Sandra Sigala, Jens Geginat, Elisa Cassinotti, Ludovica Baldari, Serena Palmieri, Alessandra Mangone, Alfredo Berruti, Emanuele Ferrante, Giovanna Mantovani, Erika Peverelli

Funding

  • Associazione Italiana per la Ricerca sul Cancro (AIRC) grant to E.P.
  • Progetti di Ricerca di Interesse Nazionale (PRIN) grants to E.P.
  • Ricerca Corrente Funds from the Italian Ministry of Health to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan

Cite

APA

Esposito, E., Marra, G., Catalano, R., Maioli, S., Nozza, E., Barbieri, A. M., Hantel, C., Di Dalmazi, G., Sigala, S., Geginat, J., Cassinotti, E., Baldari, L., Palmieri, S., Mangone, A., Berruti, A., Ferrante, E., Mantovani, G., & Peverelli, E. (2025). Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas. International Journal of Cancer. https://doi.org/10.1002/ijc.35239

Vancouver

Esposito E, Marra G, Catalano R, Maioli S, Nozza E, Barbieri AM, et al. Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas. International Journal of Cancer. 2025. doi:10.1002/ijc.35239

BibTeX
@article{Esposito2025,
  author = {Esposito, Emanuela and Marra, Giusy and Catalano, Rosa and Maioli, Sara and Nozza, Emma and Barbieri, Anna Maria and Hantel, Constanze and Di Dalmazi, Guido and Sigala, Sandra and Geginat, Jens and Cassinotti, Elisa and Baldari, Ludovica and Palmieri, Serena and Mangone, Alessandra and Berruti, Alfredo and Ferrante, Emanuele and Mantovani, Giovanna and Peverelli, Erika},
  title = {Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35239}
}
Start for free →